Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 16, Issue 7, 2010, Pages 888-892

  De Stefano, Nicola ^a   Curtin, Franóois ^b,c   Stubinski, Bettina ^b,c   Blevins, Gregg ^d   Drulovic, Jelena ^e   Issard, Delphine ^b,c   Shotekov, Penko ^f   Gasperini, Claudio ^g  

^a UNIVERSITY OF SIENA   (Italy)

^b MERCK SERONO S A   (Switzerland)

^c MERCK KGAA   (Germany)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF BELGRADE   (Serbia)

^f Clinic of Neurology   (Bulgaria)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

efficacy; interferon beta 1a; magnetic resonance imaging; randomized controlled trial; relapsing remitting multiple sclerosis

Indexed keywords

BETA1A INTERFERON; PLACEBO; BETA INTERFERON; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BRAIN; DRUG EFFECTS; EUROPE; MEDICINAL CHEMISTRY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

BRAIN; CHEMISTRY, PHARMACEUTICAL; DOUBLE-BLIND METHOD; EUROPE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955044842     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510362442     Document Type: Article

References (7)

1. Giovannoni G., Barbarash O., Casset-Semanaz F., et al. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 2009 ; 15: 219-228.
2. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121-127.
3. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452.
4. Rovaris M., Inglese M., van Schijndel RA, et al. Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. J Neurol 2000 ; 247: 960-965.
5. Li DK, Paty DW, UBC MS MRI Analysis Research Group, / PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999 ; 46: 197-206.
6. Sormani MP, Bruzzi P., Miller DH, Gasperini C., Barkhof F., Filippi M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci 1999 ; 163: 74-80.
7. Zhao Y., Traboulsee A., Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis. Neurol 2008 ; 70: 1092-1097.